Sian E Harding:国立心肺研究院(NHL)、Imperial大学临床药理学教授,往届国际心脏研究学会(ISHR)欧洲分会主席,AHA/ESC/ISHR理事,研究领域:心力衰竭的心肌细胞功能;调节心肌细胞功能的基因治疗;源自胚胎干细胞的心肌细胞特征及其在心脏修复、组织工程和药物转运中的作用。
《国际循环》:对于胚胎干细胞的来源通常存在争议,在美国情况可能更为严重。从医学或伦理学的角度,您如何看待这一问题?目前英国对这个问题有哪些看法?美国和欧洲可能会有所不同,您能否简单评价?
<International Circulation>:There is some controversy over the sources of embryonic stem cells. How can we deal with these ethical questions?
Harding教授:英国的立场通常是接受大多数事物,但是监管机构非常重视胚胎干细胞来源的伦理学问题。目前英国的情况是可以进口干细胞,但是必需通过英国干细胞银行,干细胞的来源是否符合伦理学和干细胞的使用还需要获得批准,因此都是在重大情况下才使用干细胞。也就是有一个宽松但同时处于严格监管下的使用环境。事实上,我们当然知道诱导性多能干细胞可以分化为心肌细胞,我想将来很可能会转向只使用诱导性多能干细胞。从目前来看,诱导性多能干细胞能够很好地取代胚胎干细胞,我想我们目前正在努力做到这一点。
Prof.Harding: The UK position has been to accept but legislate strongly about the ethical nature of what you are using. The situation in the UK at the moment is that you can import all the cell lines, but through the UK stem cell bank, and that should be approved in terms of the ethical provenance of the cells and also approved in terms of the use of the cells so that they are not being used for trivial purposes. Therefore, it is a liberal but highly regulated environment. In fact, because of the potential of the induced pluripotent cells, I think it is very likely that<